Cyient Q3 Review - Robust ER&D Outlook; Attractive Valuation Key Positive: IDBI Capital

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..IDBI Capital Report.Cyient Ltd. reported healthy set of Q3 FY22 numbers with IT services revenues increasing 4.4% QoQ in constant currency terms and services Ebit margins remaining flat at 15.6%. The company has also won seven large deals with total contract potential of ~$68.8 million (six from services and one from design-led manufacturing) which represent healthy growth in coming quarters. Cyient’s order book in IT services has also improved 63.6% QoQ to $200.6 million. This coupled with healthy growth in top 30 accounts (up 15% YoY), new age tech (up 22% YoY in Q3 FY22), double digit growth for next two years, improving margin trajectory (14% in near term and 15.5% in medium term) and investment in leadership to drive growth bodes well for the company..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Cyient Q3 Review - Robust ER&D Outlook; Attractive Valuation Key Positive: IDBI Capital

Cyient Q3 Review - Robust ER&D Outlook; Attractive Valuation Key Positive: IDBI Capital

Choose a plan